Algoritmus liečby glukokortikoidmi indukovanej osteoporózy

Vnitrni Lekarstvi

Volumn 55, Issue 5, 2009, Pages 506-511

  Payer, J ^a   Killinger, Z ^a   Brazdilova K ^a  

^a V interná klinika Lekárskej fakulty UK a FNsP Bratislava ^*  (El Salvador)

Author keywords

Bisphosphonates; Bone density; Calcium and vitamin D; Glucocorticoid induced osteoporosis; Osteoporotic fractures; Teriparatide

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; PARATHYROID HORMONE[1-34]; VITAMIN D;

BONE DENSITY; HYPERADRENOCORTICISM; OSTEOPOROSIS; PATHOLOGIC FRACTURE; REVIEW; RISK FACTOR; CHEMICALLY INDUCED DISORDER; HUMAN;

BONE DENSITY; FRACTURES, SPONTANEOUS; GLUCOCORTICOIDS; HUMANS; OSTEOPOROSIS;

EID: 67549140731     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (30)

1. Payer J, Killinger Z. Kostne zmeny pri hyperkorticizme. Rheumatol 1999; 13: 181-183.
2. Van Staa TP, Leufkens HC, Cooper C. The epidemiology of corticosteroid-in-duced osteoporosis: a meta-analysis. Os-teoporos lnt2002; 13: 777-787.
3. Zikán V. Glukokortikoidy a osteoporóza. Vnitř Lék 2007; 53: 831-840.
4. Van Staa TP, Leufkens HGM, Aben-haim L et al. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatol 2000; 39: 1383-1389.
5. Van Staa T, Leufkens HGM, Abenhaim L et al. Use of oral corticosteroids and risk of fractures. J Bone Miner Res 2000; 15: 993-1000.
6. De Gregorio LH, Lacativa PG, Melazzi AC et al. Glucocorticoid-induced osteoporosis. Arq Bras Endocrinol Metabol 2006; 50:793-801.
7. Van Staa TP. The pathogenesis, epidemiology and management of glucocorticoid-induced osteoporosis. Calcif Tissue lnt2006;79: 129-137.
8. KanisJAJohnell O, Oden A et al. FRAX and the assessment of fracture probability in men and women from the UK. Osteopo-roslnt 2008; 19: 385-397.
9. Payer J, Rovenský J, Killinger Z. Lexikón osteoporózy. SAP 2007; 30.
10. Alesci S, De Martino MU, Ilias I et al. Glucocorticoid-induced Osteoporosis: From Basic Mechanisms to Clinical Aspects. Neuroimmunomodulation 2005; 12: 1-19.
11. Aagaard EM, Lin P, Modin GW et al. Prevention of glucocorticoid-induced osteoporosis: provider practice at an urban county hospital. Am J Med 1999; 107: 456-460.
12. Lee YH, Lim YW, Ling PS et al. Inadequate dietary calcium intake in elderly patients with hip fractures. Singapore Med J 2007; 48: 1117-1121.
13. Štěpán J. Účinnost antiresorpční léčby postmenopauzální osteoporózy. Vnitř Lék 2007; 53: 293-299.
14. Lems WF, Van Veen GJ, Gerrits Ml et al. Effect of low-dose prednisone (with calcium and calcitriol supplementation) on calcium and bone metabolism in healthy volunteers. BrJ Rheumatol 1998; 37: 27-33.
15. Sambrook P, Birmingham J, Kelly P et al. Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin. N Engl J Med 1993; 328: 1747-1752.
16. Richy F, Ethgen O, Bruyere O et al. Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate. Ost lnt2004; 14:301-310.
17. Mok CC, Tong KH, To CH et al. Rised-ronate for prevention of bone mineral density loss in patients receiving high-dose glu-cocorticoids: a randomized double-blind placebo-controlled trial. Ost Int 2008; 19: 357-364.
18. Ringe JD, Dorst A, Faber H et al. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Ost Int 2003; 14:801-807.
19. Adachi JD, Bensen WG, Bell MJ et al. Salmon calcitonin nasal spray in the prevention of corticosteroid-induced osteoporosis. Br J Rheumatol 1997; 36: 255-259.
20. Cruse LM, Valeriano J, Vasey FB et al. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. J Clin Rheumatol 2006; 12: 221-225.
21. Yamada H. Long-term effect of 1 alpha-hydroxyvitamin D, calcium and thiazide administration on glucocorticoid-induced osteoporosis. Nippon Nai-bunpi Gakkai Zasshi 1989; 65: 603-14.
22. Štěpán J. Osteoporóza v praxi. Praha: Triton 1997; 156.
23. Saag KG, Shane E, Boonen S et al. Te-riparatide or alendronate in glucocorticoid-induced osteoporosis. N Engl J Med 2007; 357: 2028-2039.
24. Štěpán J. Glukokortikoidy induko-vana osteoporoza: Nove moznosti pre-vence a léčby. Interni Med 2008; 10: 323-326.
25. Čierny D, Killinger Z, Payer J. Posta-venie teriparatidu a intaktného parathor-monu v liečbe osteoporózy. Slov Lek 2007; 17: 226-230.
26. Recommendations for the Prevention and Treatment of Glucocorticoid- induced Osteoporosis. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-induced Osteoporosis 2001; 44: 1496-1503.
27. Saag KG. Prevention of Glucocorticoid-induced Osteoporosis. South Med J 2004; 97: 555-558.
28. Geusens PP, de Nijs RNJ, Lems WF et al. Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology. Ann Rheum Dis 2004; 63: 324-325.
29. Kanis JA, Stevenson M, McCloskey EV et al. Glucocorticoid-induced osteoporosis: a systematic review and cost-utility analysis. Health Technol Assess 2007; 11: 1-231.
30. Odborné usmernenie MZ SR pre diagnostiku a liečbu osteoporózy. Vestni'k MZSR2006; 54: 9-16.